• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region.中东北欧地区艾滋病毒感染者的 COVID-19 疫苗接种国家战略。
HIV Med. 2022 May;23(5):546-552. doi: 10.1111/hiv.13194. Epub 2021 Oct 26.
2
The Management of HIV Care Services in Central and Eastern Europe: Data from the Euroguidelines in Central and Eastern Europe Network Group.中东欧地区的艾滋病毒护理服务管理:来自中东欧 Euroguidelines 网络组的数据。
Int J Environ Res Public Health. 2022 Jun 21;19(13):7595. doi: 10.3390/ijerph19137595.
3
Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.人乳头瘤病毒流行率和型别分布、在中欧和东欧的宫颈癌筛查做法以及当前疫苗接种实施状况。
Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029.
4
HIV care in times of the COVID-19 crisis - Where are we now in Central and Eastern Europe?HIV 护理在 COVID-19 危机时期——在中东欧地区我们现在处于什么位置?
Int J Infect Dis. 2020 Jul;96:311-314. doi: 10.1016/j.ijid.2020.05.013. Epub 2020 May 11.
5
Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.中东北欧和中亚地区人乳头瘤病毒相关疾病的模式和趋势。
Vaccine. 2013 Dec 31;31 Suppl 7:H32-45. doi: 10.1016/j.vaccine.2013.02.071.
6
Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report.中东欧地区欧洲指南(ECEE)会议与《华沙宣言》——一份全面的会议报告
HIV Med. 2017 May;18(5):370-375. doi: 10.1111/hiv.12436. Epub 2016 Aug 24.
7
COVID-19 Vaccine Uptake Among People Living with HIV.COVID-19 疫苗在 HIV 感染者中的接种情况。
AIDS Behav. 2022 Jul;26(7):2224-2228. doi: 10.1007/s10461-021-03570-9. Epub 2022 Jan 7.
8
Risk of breakthrough infection and hospitalisation after COVID-19 primary vaccination by HIV status in four Italian regions during 2021.2021 年意大利四个地区按 HIV 状况划分的 COVID-19 初级疫苗接种后突破性感染和住院的风险。
BMC Public Health. 2024 Jun 11;24(1):1569. doi: 10.1186/s12889-024-19071-y.
9
Current status of human papillomavirus vaccination implementation in central and eastern Europe.中东欧地区人乳头瘤病毒疫苗接种的现状
Acta Dermatovenerol Alp Pannonica Adriat. 2013;22(1):21-5.
10
The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease-A report from Central and Eastern Europe.HIV 阳性患者中轻症/无症状和中重度 COVID-19 患者的特征——来自中东欧的报告。
Int J Infect Dis. 2021 Mar;104:293-296. doi: 10.1016/j.ijid.2020.12.026. Epub 2020 Dec 14.

引用本文的文献

1
First real-life data on COVID-19 vaccine effectiveness against hospitalisation and severe disease from the eastern part of the WHO European Region.来自世界卫生组织欧洲区域东部的关于新冠病毒疫苗对住院治疗和重症疾病有效性的首批实际数据。
Lancet Reg Health Eur. 2024 Nov 5;47:101130. doi: 10.1016/j.lanepe.2024.101130. eCollection 2024 Dec.
2
Online course on vaccinating people with HIV/AIDS - effectiveness in the knowledge of nursing professionals.在线艾滋病毒/艾滋病疫苗接种课程 - 对护理专业人员知识的影响。
Rev Lat Am Enfermagem. 2024 Aug 12;32:e4278. doi: 10.1590/1518-8345.7004.4278. eCollection 2024.
3
Immunological and Clinical Responses to Vaccinations among Adults Living with HIV.感染艾滋病毒的成年人对疫苗接种的免疫和临床反应。
Life (Basel). 2024 Apr 24;14(5):540. doi: 10.3390/life14050540.
4
COVID-19 Vaccine Hesitancy Among People Living with HIV: A Systematic Review and Meta-Analysis.COVID-19 疫苗犹豫在 HIV 感染者中的研究:系统综述和荟萃分析。
AIDS Behav. 2024 Jul;28(7):2183-2192. doi: 10.1007/s10461-024-04344-9. Epub 2024 Apr 16.
5
Tenofovir-Containing Antiretroviral Therapy and Clinical Outcomes of SARS-CoV-2 Infection in People Living with HIV.含替诺福韦的抗逆转录病毒治疗与 HIV 感染者感染 SARS-CoV-2 的临床结局。
Viruses. 2023 May 9;15(5):1127. doi: 10.3390/v15051127.
6
The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland.HIV阳性患者接种新冠疫苗的临床有效性和安全性:来自波兰的观察性研究数据
Vaccines (Basel). 2023 Feb 22;11(3):514. doi: 10.3390/vaccines11030514.
7
Non-HIV-related comorbidities and uncontrolled HIV replication are independent factors increasing the odds of hospitalization due to COVID-19 among HIV-positive patients in Poland.在波兰,非 HIV 相关合并症和 HIV 复制失控是导致 HIV 阳性患者因 COVID-19 住院的独立危险因素。
Infection. 2023 Apr;51(2):379-387. doi: 10.1007/s15010-022-01887-8. Epub 2022 Jul 27.
8
Progressive Worsening of Neurological Manifestations in HIV-Associated Opportunistic Central Nervous System (CNS) Infection Patients After COVID-19 Vaccinations: A Possible Co-Incidence Causality.HIV 相关机会性中枢神经系统(CNS)感染患者在接种 COVID-19 疫苗后神经表现逐渐恶化:可能存在合并因果关系。
Am J Case Rep. 2022 May 25;23:e936257. doi: 10.12659/AJCR.936257.

本文引用的文献

1
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial.腺病毒载体新冠疫苗(AZD1222)在人类免疫缺陷病毒(HIV)感染者中针对严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的安全性和免疫原性:一项 2/3 期临床试验的单臂亚研究。
Lancet HIV. 2021 Aug;8(8):e474-e485. doi: 10.1016/S2352-3018(21)00103-X. Epub 2021 Jun 18.
2
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.NVX-CoV2373 新冠疫苗对 B.1.351 变异株的有效性。
N Engl J Med. 2021 May 20;384(20):1899-1909. doi: 10.1056/NEJMoa2103055. Epub 2021 May 5.
3
COVID-19 in People Living with HIV: A Systematic Review and Meta-Analysis.中文译文:HIV 感染者中的 COVID-19:系统评价和荟萃分析。
Int J Environ Res Public Health. 2021 Mar 30;18(7):3554. doi: 10.3390/ijerph18073554.
4
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
5
Immune deficiency is a risk factor for severe COVID-19 in people living with HIV.免疫缺陷是 HIV 感染者发生重症 COVID-19 的一个风险因素。
HIV Med. 2021 May;22(5):372-378. doi: 10.1111/hiv.13037. Epub 2020 Dec 27.
6
The characteristics of HIV-positive patients with mild/asymptomatic and moderate/severe course of COVID-19 disease-A report from Central and Eastern Europe.HIV 阳性患者中轻症/无症状和中重度 COVID-19 患者的特征——来自中东欧的报告。
Int J Infect Dis. 2021 Mar;104:293-296. doi: 10.1016/j.ijid.2020.12.026. Epub 2020 Dec 14.
7
HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform.HIV 感染与 COVID-19 死亡:基于人群的英国初级保健数据队列分析及 OpenSAFELY 平台内的全国死亡登记数据关联分析
Lancet HIV. 2021 Jan;8(1):e24-e32. doi: 10.1016/S2352-3018(20)30305-2. Epub 2020 Dec 11.
8
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
9
Risk factors for severe and critically ill COVID-19 patients: A review.COVID-19 患者重症和危重症的危险因素:综述。
Allergy. 2021 Feb;76(2):428-455. doi: 10.1111/all.14657. Epub 2020 Dec 4.
10
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study.在 ISARIC 世界卫生组织(WHO)临床特征协议(英国)中,人类免疫缺陷病毒(HIV)感染者因 2019 年冠状病毒病(COVID-19)相关住院的结果:一项前瞻性观察研究。
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106. doi: 10.1093/cid/ciaa1605.

中东北欧地区艾滋病毒感染者的 COVID-19 疫苗接种国家战略。

National strategies for vaccination against COVID-19 in people living with HIV in Central and Eastern European region.

机构信息

Department of Infectious Diseases, 1st Faculty of Medicine, Charles University in Prague and Faculty Hospital Bulovka, Prague, Czech Republic.

Department of Adults' Infectious Diseases, Hospital for Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.

出版信息

HIV Med. 2022 May;23(5):546-552. doi: 10.1111/hiv.13194. Epub 2021 Oct 26.

DOI:10.1111/hiv.13194
PMID:34704331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8653080/
Abstract

INTRODUCTION

People living with HIV (PLWH) are at higher risk of poorer COVID-19 outcomes. Vaccination is a safe and effective method of prevention against many infectious diseases, including COVID-19. Here we investigate the strategies for national COVID-19 vaccination programmes across central and eastern Europe and the inclusion of PLWH in vaccination programmes.

METHODS

The Euroguidelines in Central and Eastern Europe Network Group consists of experts in the field of infectious diseases from 24 countries in the region. Between 1 November 2020 and 19 March 2021 the group proceeded an on-line survey consisting of 20 questions.

RESULTS

Twenty-two countries (out of 24 invited) participated in the survey and 20/22 countries in the period between December 2020 and March 2021 had already started their COVID-19 vaccination programme. In total, seven different vaccines were used by participating countries. In 17/21 countries (81%), vaccinated persons were centralized within the national registry. In 8/21 countries (38%) PLWH were prioritized for vaccination (the Czech Republic, Greece, Hungary, Lithuania, Montenegro, Romania, Slovakia, Slovenia) and the Czech Republic, Greece and Serbia had put in place national guidelines for vaccination of PLWH. In 14/20 countries (70%) vaccination was only provided by designated centres. Eighteen respondents (18/21; 85.7%) reported that they planned to follow up HIV patients vaccinated against COVID-19, mainly by measuring antibody levels and checking COVID-19 incidence (11/21; 52.3%).

CONCLUSIONS

This survey-based study suggests that there are significant differences in terms of prioritizing PLWH, the types of vaccines used, vaccination coverage, and the development and implementation of a vaccination programmes within the region. Regardless of heterogenicity and existing barriers within the region, systematic vaccination in PLWH should have the highest priority, especially in those with severe immunodeficiency, risk factors, and in the elderly, aiming for prompt and high vaccination coverage.

摘要

简介

感染 HIV 的人(PLWH)患 COVID-19 的风险更高。疫苗接种是预防包括 COVID-19 在内的许多传染病的安全有效方法。在这里,我们研究了中东欧国家的 COVID-19 疫苗接种计划策略以及将 PLWH 纳入疫苗接种计划。

方法

东欧和中欧 Euroguidelines 网络集团由该地区 24 个国家的传染病专家组成。2020 年 11 月 1 日至 2021 年 3 月 19 日,该小组进行了一项包含 20 个问题的在线调查。

结果

24 个受邀国家中有 22 个国家参与了调查,2020 年 12 月至 2021 年 3 月期间 20/22 个国家已经开始了 COVID-19 疫苗接种计划。总共有七个不同的疫苗被参与国家使用。在 21 个国家中的 17 个(81%),接种者集中在国家登记册中。在 21 个国家中的 8 个(38%),PLWH 被优先接种疫苗(捷克共和国、希腊、匈牙利、立陶宛、黑山、罗马尼亚、斯洛伐克、斯洛文尼亚),捷克共和国、希腊和塞尔维亚已经制定了 PLWH 疫苗接种国家指南。在 20 个国家中的 14 个(70%),疫苗接种仅由指定中心提供。21 名受访者中的 18 名(18/21;85.7%)报告说,他们计划跟踪接种 COVID-19 疫苗的 HIV 患者,主要通过测量抗体水平和检查 COVID-19 发病率(21/21;52.3%)。

结论

这项基于调查的研究表明,在优先考虑 PLWH、使用的疫苗类型、疫苗接种覆盖率以及该地区疫苗接种计划的制定和实施方面,存在显著差异。尽管该地区存在异质性和现有障碍,但应优先为 PLWH 进行系统疫苗接种,特别是在那些免疫严重缺陷、有风险因素和老年人中,以实现快速和高疫苗接种覆盖率。